Tweets
RT @drdavidliew
"I’ve always thought new RA meds get prescribed to the most risky patients, and therefore you see more adverse events.
Turns out it’s marginally true - maybe out to five years. Worth being careful of judging new meds too early!
#EULAR2024 OP0114 @karolinskainst
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Imaging in Axial Spondyloarthritis
Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.
https://t.co/SqTi4Xvoo2 https://t.co/TzZdUEkOXW
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Axial & Psoriatic Disease
Dr. Peter Nash at Eular 2024 in Vienna, Austria.
https://t.co/eHfNQgN1BQ https://t.co/Uj6AwbXj8J
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Factors Affecting Hydroxychloroquine Adherence
A study from the University of British Columbia has evaluated the trajectories of HCQ use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence.
https://t.co/kDUxVCfRGt https://t.co/1v79Vqdqo8
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
No Risk of Interstitial Lung Disease with Methotrexate Use
JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).
https://t.co/qauRelAkG0 https://t.co/bhSLYrfzlv
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA.
https://t.co/yyayyPcN9L https://t.co/4IQfmvbg4G
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Study of 2,974 SLE pts taking hydroxychloroquine (HCQ) found 584 w/ ≥1 hospitalization for SLE. Taking Lower doses of HCQ (≤5 mg/kg/d) or <400 mg/d were assoc w/ increased hospitalizations for active SLE (adjusted OR 4.20 & aOR 3.39, respectively) https://t.co/QbLBMtBO30 https://t.co/b63bC0SKsf
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
FDA has approved risankizumab (Skyrizi) to treat adults with moderately to severely active ulcerative colitis (UC), making it the IL-23 inhibitor approved for UC. Approval is based on two large phase 3 clinical trials (COMMAND, INSPIRE) https://t.co/wNSZdWWDO1 https://t.co/mlwxIrdUD2
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
JAK inhibitors have been used as adjunctive therapy to reduce flammation arising with checkpoint inhibitor use in cancer (Hodgkins, Lung CA), using itacitinib w/ pembrolizumab or ruxolitinib & nivolumab improved trial outcomes https://t.co/eF6wO72D80 https://t.co/IFDYuI71X5
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/NcxReWk83n https://t.co/FSMx22XiNo
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT:
data now out to 60w
good humoral and cellular response in most, even without MTX withheld
(& good safety too)
Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/y3UvOF4M5i https://t.co/iSUrkhIXbh
Dr. John Cush @RheumNow ( View Tweet )
1 year 10 months ago
